Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥61.35 Million ≈ $8.98 Million USD) by net assets (CN¥2.87 Billion ≈ $419.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chengdu Easton Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Chengdu Easton Biopharmaceuticals Co Ltd (688513) total liabilities for a breakdown of total debt and financial obligations.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TriCo Bancshares
NASDAQ:TCBK
|
0.034x |
|
China Publishing & Media Hldg
SHG:601949
|
0.023x |
|
Nexa Resources SA
NYSE:NEXA
|
0.153x |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
-0.246x |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
-0.128x |
|
Bonesupport Holding AB
ST:BONEX
|
0.085x |
|
Datang Telecom Technology Co Ltd
SHG:600198
|
0.015x |
|
Systemair AB
ST:SYSR
|
0.056x |
Annual Cash Flow Conversion Efficiency for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.70 Billion ≈ $394.79 Million |
CN¥263.24 Million ≈ $38.52 Million |
0.098x | -7.71% |
| 2023-12-31 | CN¥2.60 Billion ≈ $380.96 Million |
CN¥275.25 Million ≈ $40.28 Million |
0.106x | +70.09% |
| 2022-12-31 | CN¥2.44 Billion ≈ $357.70 Million |
CN¥151.94 Million ≈ $22.23 Million |
0.062x | -3.49% |
| 2021-12-31 | CN¥2.29 Billion ≈ $335.34 Million |
CN¥147.60 Million ≈ $21.60 Million |
0.064x | -13.79% |
| 2020-12-31 | CN¥2.10 Billion ≈ $306.60 Million |
CN¥156.52 Million ≈ $22.90 Million |
0.075x | -63.26% |
| 2019-12-31 | CN¥697.44 Million ≈ $102.06 Million |
CN¥141.83 Million ≈ $20.75 Million |
0.203x | -29.02% |
| 2018-12-31 | CN¥582.19 Million ≈ $85.19 Million |
CN¥166.79 Million ≈ $24.41 Million |
0.286x | +48.85% |
| 2017-12-31 | CN¥445.28 Million ≈ $65.16 Million |
CN¥85.70 Million ≈ $12.54 Million |
0.192x | -29.27% |
| 2016-12-31 | CN¥389.79 Million ≈ $57.04 Million |
CN¥106.06 Million ≈ $15.52 Million |
0.272x | +44.32% |
| 2015-12-31 | CN¥268.21 Million ≈ $39.25 Million |
CN¥50.57 Million ≈ $7.40 Million |
0.189x | -17.97% |
| 2014-12-31 | CN¥203.25 Million ≈ $29.74 Million |
CN¥46.71 Million ≈ $6.84 Million |
0.230x | +37.82% |
| 2013-12-31 | CN¥168.62 Million ≈ $24.67 Million |
CN¥28.12 Million ≈ $4.11 Million |
0.167x | -- |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more